Drug Profile

Research programme: JNK mitogen activated protein kinase inhibitors - Baylor College of Medicine/Celmatix

Latest Information Update: 22 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Baylor College of Medicine
Developer Baylor College of Medicine; Celmatix
Class
Mechanism of Action JNK mitogen-activated protein kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Endometriosis

Most Recent Events

31 Jan 2025 Preclinical development in Endometriosis in USA (unspecified route) prior to January 2025 (Celmatix pipeline, August 2025)
08 Jan 2025 Celmatix in-licenses the JNK inhibitor scaffolds from Baylor College of Medicine (Celmatix pipeline, August 2025)
08 Jan 2025 Pharmacodynamics data from a preclinical study in Endometriosis released by Celmatix

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com